1 min read
Add as a preferred source on GoogleCareDx Reports 39% Revenue Growth as Testing Volume Climbs 51%
The diagnostics company recorded $139 million in third-quarter revenue and about 75,900 testing-services procedures.
CareDx recorded $139 million in third-quarter 2026 revenue, a 39% increase from a year earlier. Testing-services volume rose 51% to about 75,900 for the quarter ended Sept. 30.
The company focuses on diagnostics for transplant, specialty oncology and cell therapy. Its testing services include NavDx, a blood-based test used to detect and monitor certain HPV-associated cancers.
CareDx completed its acquisition of Naveris on July 1, 2026. The deal added NavDx to the company’s portfolio.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.